Marvel Biosciences Corp.
MBCOF
$0.0629
-$0.0021-3.23%
OTC PK
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 701.80K | 667.10K | 678.40K | 772.10K | 921.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 945.00K | 742.00K | 900.90K | 1.43M | 1.75M |
| Operating Income | -945.00K | -742.00K | -900.90K | -1.43M | -1.75M |
| Income Before Tax | -1.20M | -1.03M | -1.21M | -1.56M | -1.87M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.20 | -1.03 | -1.21 | -1.56 | -1.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.20M | -1.03M | -1.21M | -1.56M | -1.87M |
| EBIT | -945.00K | -742.00K | -900.90K | -1.43M | -1.75M |
| EBITDA | -- | -- | -- | -774.40K | -1.26M |
| EPS Basic | -0.03 | -0.03 | -0.03 | -0.04 | -0.05 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.03 |
| EPS Diluted | -0.03 | -0.03 | -0.03 | -0.04 | -0.05 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.03 |
| Average Basic Shares Outstanding | 169.86M | 164.86M | 159.86M | 159.15M | 159.15M |
| Average Diluted Shares Outstanding | 169.86M | 164.86M | 159.86M | 159.15M | 159.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |